{"id":"https://openalex.org/W4206337677","doi":"https://doi.org/10.1200/jco.2022.40.4_suppl.121","title":"A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.","display_name":"A phase 1b multitumor cohort study of cabozantinib plus atezolizumab in advanced solid tumors (COSMIC-021): Results of the colorectal cancer cohort.","publication_year":2022,"publication_date":"2022-01-19","ids":{"openalex":"https://openalex.org/W4206337677","doi":"https://doi.org/10.1200/jco.2022.40.4_suppl.121"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2022.40.4_suppl.121","doi":"https://doi.org/10.1200/jco.2022.40.4_suppl.121","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.4_suppl.121","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045494904","display_name":"Thomas Adam Abrams","orcid":"https://orcid.org/0000-0003-3101-1573","observed_orcids":["https://orcid.org/0000-0003-3101-1573"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas Adam Abrams","raw_affiliation_strings":["Dana-Farber Cancer Institute, Boston, MA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dana-Farber Cancer Institute, Boston, MA;","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086948150","display_name":"Syed Mohammad Ali Kazmi","orcid":"https://orcid.org/0000-0002-3367-367X","observed_orcids":["https://orcid.org/0000-0002-3367-367X"]},"institutions":[{"id":"https://openalex.org/I867280407","display_name":"The University of Texas Southwestern Medical Center","ror":"https://ror.org/05byvp690","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I867280407"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Syed Mohammad Ali Kazmi","raw_affiliation_strings":["UT Southwestern, Dallas, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UT Southwestern, Dallas, TX;","institution_ids":["https://openalex.org/I867280407"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039736511","display_name":"Ira Seth Winer","orcid":"https://orcid.org/0000-0001-6056-8296","observed_orcids":["https://orcid.org/0000-0001-6056-8296"]},"institutions":[{"id":"https://openalex.org/I185443292","display_name":"Wayne State University","ror":"https://ror.org/01070mq45","country_code":"US","type":"education","lineage":["https://openalex.org/I185443292"]},{"id":"https://openalex.org/I4210090317","display_name":"The Barbara Ann Karmanos Cancer Institute","ror":"https://ror.org/00ee40h97","country_code":"US","type":"facility","lineage":["https://openalex.org/I2800590384","https://openalex.org/I4210090317"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ira Seth Winer","raw_affiliation_strings":["Department of Obstetrics and Gynecology, Karmanos Cancer Institute, Wayne State University, Detroit, MI;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics and Gynecology, Karmanos Cancer Institute, Wayne State University, Detroit, MI;","institution_ids":["https://openalex.org/I185443292","https://openalex.org/I4210090317"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043675371","display_name":"Vivek Subbiah","orcid":"https://orcid.org/0000-0002-6064-6837","observed_orcids":["https://orcid.org/0000-0002-6064-6837"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Vivek Subbiah","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069777765","display_name":"Gerald Steven Falchook","orcid":"https://orcid.org/0000-0001-9165-2191","observed_orcids":["https://orcid.org/0000-0001-9165-2191"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gerald Steven Falchook","raw_affiliation_strings":["Sarah Cannon Research Institute, Denver, CO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Denver, CO;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081272862","display_name":"Matthew J. Reilley","orcid":"https://orcid.org/0000-0002-4725-0459","observed_orcids":["https://orcid.org/0000-0002-4725-0459"]},"institutions":[{"id":"https://openalex.org/I2799765794","display_name":"University of Virginia Health System","ror":"https://ror.org/00wn7d965","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799765794"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew Reilley","raw_affiliation_strings":["Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA;","institution_ids":["https://openalex.org/I2799765794"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001545425","display_name":"Paul Raymond Kunk","orcid":"https://orcid.org/0000-0001-7416-513X","observed_orcids":["https://orcid.org/0000-0001-7416-513X"]},"institutions":[{"id":"https://openalex.org/I2799765794","display_name":"University of Virginia Health System","ror":"https://ror.org/00wn7d965","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799765794"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul Raymond Kunk","raw_affiliation_strings":["Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA;","institution_ids":["https://openalex.org/I2799765794"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029455802","display_name":"Sanjay Goel","orcid":"https://orcid.org/0000-0002-2798-7568","observed_orcids":["https://orcid.org/0000-0002-2798-7568"]},"institutions":[{"id":"https://openalex.org/I1335289525","display_name":"Montefiore Medical Center","ror":"https://ror.org/044ntvm43","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1335289525","https://openalex.org/I19772626"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sanjay Goel","raw_affiliation_strings":["Department of Medical Oncology, Montefiore Medical Center, Bronx, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Montefiore Medical Center, Bronx, NY;","institution_ids":["https://openalex.org/I1335289525"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029563022","display_name":"Ignacio Garrido\u2010Laguna","orcid":"https://orcid.org/0000-0003-2273-9028","observed_orcids":["https://orcid.org/0000-0003-2273-9028"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]},{"id":"https://openalex.org/I2801159745","display_name":"Huntsman Cancer Institute","ror":"https://ror.org/03v7tx966","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2801159745","https://openalex.org/I4210148268"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ignacio Garrido-Laguna","raw_affiliation_strings":["Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT;","institution_ids":["https://openalex.org/I223532165","https://openalex.org/I2801159745"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018419601","display_name":"Mark D. Kochenderfer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark D. Kochenderfer","raw_affiliation_strings":["Hematology and Medical Oncology, Blue Ridge Cancer Care, Roanoke, VA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology and Medical Oncology, Blue Ridge Cancer Care, Roanoke, VA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005051754","display_name":"Scott W. Werneke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Werneke","raw_affiliation_strings":["Exelixis, Inc., Alameda, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis, Inc., Alameda, CA;","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000959268","display_name":"Lana Andrianova","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lana Andrianova","raw_affiliation_strings":["Exelixis, Inc., Alameda, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis, Inc., Alameda, CA;","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072901091","display_name":"Ramu G. Sudhagoni","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I152988861","display_name":"Exelixis (United States)","ror":"https://ror.org/01e3jga91","country_code":"US","type":"company","lineage":["https://openalex.org/I152988861"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramu Sudhagoni","raw_affiliation_strings":["Exelixis, Inc., Alameda, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Exelixis, Inc., Alameda, CA;","institution_ids":["https://openalex.org/I152988861"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5111980609","display_name":"Scott Paulson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott Paulson","raw_affiliation_strings":["Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":10,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":21,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"40","issue":"4_suppl","first_page":"121","last_page":"121"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.7943999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.7943999767303467,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.20319999754428864,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10335","display_name":"Colorectal Cancer Surgical Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cabozantinib","display_name":"cabozantinib","score":0.9950000047683716},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9769999980926514},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.753000020980835},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.6779999732971191},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.6340000033378601},{"id":"https://openalex.org/keywords/ras-mutations","display_name":"RAS mutations","score":0.5849999785423279},{"id":"https://openalex.org/keywords/microsatellite-instability","display_name":"microsatellite instability","score":0.6010000109672546},{"id":"https://openalex.org/keywords/mismatch-repair-deficiency","display_name":"mismatch repair deficiency","score":0.6470000147819519},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5180000066757202},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7720000147819519},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.753000020980835},{"id":"https://openalex.org/keywords/treatment-related-adverse-events","display_name":"treatment-related adverse events","score":0.7089999914169312},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.38999998569488525}],"concepts":[{"id":"https://openalex.org/C2781064419","wikidata":"https://www.wikidata.org/wiki/Q795057","display_name":"Cabozantinib","level":3,"score":0.8927924633026123},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8592838644981384},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.7921960353851318},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6508602499961853},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6387529373168945},{"id":"https://openalex.org/C2780259306","wikidata":"https://www.wikidata.org/wiki/Q412197","display_name":"Irinotecan","level":4,"score":0.5717885494232178},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.5284654498100281},{"id":"https://openalex.org/C203092338","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Clinical endpoint","level":3,"score":0.5053927898406982},{"id":"https://openalex.org/C2780962732","wikidata":"https://www.wikidata.org/wiki/Q422327","display_name":"Oxaliplatin","level":4,"score":0.43060022592544556},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4086977541446686},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.3072950839996338},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.17895516753196716},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.16719356179237366}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2022.40.4_suppl.121","doi":"https://doi.org/10.1200/jco.2022.40.4_suppl.121","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2022.40.4_suppl.121","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[{"score":0.8399999737739563,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320312140","display_name":"Exelixis","ror":"https://ror.org/01e3jga91"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4294934943","https://openalex.org/W3213582601","https://openalex.org/W3031439708","https://openalex.org/W4281646247","https://openalex.org/W3029709563","https://openalex.org/W4308395434","https://openalex.org/W4324136481","https://openalex.org/W4393002508","https://openalex.org/W4283781518","https://openalex.org/W4407719982"],"abstract_inverted_index":{"121":[0],"Background:":[1],"Cabozantinib,":[2],"a":[3],"multiple":[4],"receptor":[5],"tyrosine":[6],"kinase":[7],"inhibitor,":[8,34,187],"promotes":[9],"an":[10,32,62],"immune-permissive":[11],"environment":[12],"which":[13],"may":[14],"enhance":[15],"the":[16,26,153,257,275],"activity":[17,216,300],"of":[18,28,65,87,137,182,207,250],"immune":[19],"checkpoint":[20],"inhibitors.":[21],"COSMIC-021":[22],"(NCT03170960)":[23],"is":[24],"evaluating":[25],"combination":[27],"cabozantinib":[29,108,163],"with":[30,37,45,52,59,219,223,240,301,306],"atezolizumab,":[31],"anti-PD-L1":[33],"in":[35,42,194,217,254,272,304],"patients":[36,43],"advanced":[38,309],"solid":[39],"tumors.":[40],"Outcomes":[41],"(pts)":[44],"metastatic":[46],"colorectal":[47],"cancer":[48],"(mCRC)":[49],"previously":[50,307],"treated":[51,308],"fluoropyrimidine-containing":[53],"therapy":[54,89,92],"are":[55],"presented.":[56],"Methods:":[57],"Pts":[58,106],"mCRC":[60,220],"and":[61,143,156,233,235,265,283],"ECOG":[63,175],"PS":[64,176],"0\u20131":[66],"who":[67],"progressed":[68],"during":[69],"or":[70,78],"following":[71],"systemic":[72],"chemotherapy":[73],"including":[74,90],"fluoropyrimidine":[75],"plus":[76,113,164,212,295],"oxaliplatin":[77],"irinotecan":[79],"were":[80,93,104,149,260,278,291],"eligible.":[81],"Up":[82],"to":[83],"2":[84,179],"prior":[85,180,185],"lines":[86,181],"anti-cancer":[88],"EGFR-targeted":[91],"allowed.":[94],"Microsatellite":[95],"instability":[96],"high":[97],"(MSI-H)":[98],"and/or":[99],"mismatch":[100],"repair":[101],"(MMR)-deficient":[102],"pts":[103,161,218,305],"excluded.":[105],"received":[107,162],"40":[109],"mg":[110,116],"PO":[111],"QD":[112],"atezolizumab":[114,165,213,296],"1200":[115],"IV":[117],"Q3W.":[118],"The":[119],"primary":[120],"endpoint":[121],"was":[122,200],"objective":[123],"response":[124,138],"rate":[125],"(ORR)":[126],"per":[127],"RECIST":[128],"1.1":[129],"by":[130],"investigator.":[131],"Other":[132],"endpoints":[133],"included":[134],"safety,":[135],"duration":[136],"(DOR),":[139],"progression-free":[140],"survival":[141,145],"(PFS),":[142],"overall":[144],"(OS).":[146],"CT/MRI":[147],"scans":[148],"performed":[150],"Q6W":[151],"for":[152],"first":[154],"year":[155],"Q12W":[157],"thereafter.":[158],"Results:":[159],"31":[160],"(median":[166],"age,":[167],"60":[168],"y":[169],"[range":[170],"31,":[171],"79];":[172],"male,":[173],"58%;":[174],"1,":[177],"61%;":[178],"therapy,":[183],"71%;":[184],"EGFR":[186],"16%;":[188],"\u22653":[189],"tumor":[190],"sites,":[191],"52%;":[192],"tumors":[193],"left":[195],"colorectum,":[196],"71%).":[197],"Median":[198],"follow-up":[199],"28.1":[201],"mo":[202],"(range,":[203],"24.2,":[204],"31.3)":[205],"as":[206],"July":[208],"21,":[209],"2021.":[210],"Cabozantinib":[211,294],"demonstrated":[214,297],"clinical":[215,299],"(Table).":[221,245],"Patients":[222],"wild-type":[224],"RAS":[225],"(n":[226,242],"=":[227,243],"12)":[228],"had":[229],"numerically":[230],"longer":[231],"PFS":[232],"OS":[234],"higher":[236],"ORR":[237],"vs":[238],"those":[239],"mutations":[241],"19)":[244],"Treatment-related":[246],"adverse":[247],"events":[248,290],"(TRAEs)":[249],"any":[251],"grade":[252],"occurred":[253,271],"28":[255],"(90%);":[256],"most":[258,276],"common":[259,277],"diarrhea":[261],"(52%),":[262],"fatigue":[263,281],"(42%),":[264],"nausea":[266],"(35%).":[267],"Grade":[268,288],"3-4":[269],"TRAEs":[270],"16":[273],"(52%);":[274],"hypertension":[279],"(10%),":[280],"(6%),":[282],"lipase":[284],"increased":[285],"(6%);":[286],"no":[287],"5":[289],"reported.":[292],"Conclusions:":[293],"encouraging":[298],"manageable":[302],"toxicity":[303],"non-MSI-H/MMR-proficient":[310],"CRC.":[311],"Clinical":[312],"trial":[313],"information:":[314],"NCT03170960.":[315],"[Table:":[316],"see":[317],"text]":[318]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":3}],"updated_date":"2026-10-22T18:32:59.640997","created_date":"2022-01-25T00:00:00"}